We used the following GWAS summary datasets: attention deficit/hyperactivity disorder (ADHD) (n = 20,183 cases; 35,191 controls) 50, autism spectrum disorder (ASD) (n = 18,381 cases; 27,969 controls)41, bipolar disorder (BD) (n = 20,352 cases; 31,538 controls)51, schizophrenia (SCZ) (n = 11,260; 24,542 controls)52, major depressive disorder (MDD) (n = 246,363 cases; 561,190 controls)53, Alzheimer’s disease (AD) (n = 71,880 cases; 383,378 controls)54, Parkinson’s disease (PD) (n= 37,700 cases; 1,400,000 controls)55, multiple sclerosis (MS) (n = 4,888; 10,395 controls)56, amyotrophic lateral sclerosis (ALS) (n = 12,577; 23,475 controls)57. Since we used publicly available GWAS summary statistics, (1) no data points were excluded from analysis, (2) no statistical methods were used to pre-determine the sample size, and (3) data collection and analysis were not performed blind to the conditions of the experiments.
